During the latest earnings call, Moderna CEO Stéphane Bancel was pleased with the cost efficiency achieved during the quarter ...

Costochondritis — a benign condition that causes inflammation of the cartilage connecting your ribs to your breastbone. Also ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Addressing analysts on Moderna’s quarterly earnings call, CEO Stéphane Bancel noted that Moderna was among companies that had ...

1 "Today's approval is an example of how our mRNA platform can help address significant public health challenges like RSV," said Stéphane Bancel, Chief Executive Officer of Moderna. "As our second ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Moderna President Stephen Hoge, M.D., has taken on an expanded role, adding new responsibilities overseeing Moderna’s commercial organization. As President, Dr. Hoge will now be responsible for ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...